Doxorubicin and VEGF-targeting CRISPR/Cas9 Encapsulating Nanoparticles for Combinational Cancer Treatments
발표자
()
초록
내용
Doxorubicin (DOX) is one of the most widely used chemotherapy drugs for the treatment of cancers. However, its clinical use has been limited by the cytotoxic side effects and occurrence of drug resistance. Here, we combined doxorubicin chemotherapy with CRISPR/Cas9 mediated gene therapy for safe and efficient cancer treatments. CRISPR/Cas9 system was used to specifically target vascular endothelial growth factor (VEGF) gene. For co-delivery of DOX and CRISPR/Cas9, DOX was intercalated into DNA that encode for Cas9 and sgRNA. The Dox loaded DNA was complexed with deoxycholic acid-modified polyethyleneimine to form nanoparticles for efficient delivery to cancer cells. DOX loading, complex formation, gene editing and cancer cell viability were investigated to evaluate therapeutic efficiency and toxicity. The co-delivery of VEGF-targeted gene therapy in combination with DOX chemotherapy could be a promising approach for enhanced therapeutic efficacy while minimizing toxic side effects.